Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations
-
Published:2024-02
Issue:2
Volume:5
Page:100636
-
ISSN:2666-3643
-
Container-title:JTO Clinical and Research Reports
-
language:en
-
Short-container-title:JTO Clinical and Research Reports
Author:
Takeyasu YukiORCID,
Yoshida Tatsuya,
Masuda Ken,
Matsumoto Yuji,
Shinno Yuki,
Okuma Yusuke,
Goto Yasushi,
Horinouchi Hidehito,
Yamamoto Noboru,
Ohe Yuichiro
Reference45 articles.
1. Screening for epidermal growth factor receptor mutations in lung cancer;Rosell;N Engl J Med,2009
2. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009
3. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010
4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011
5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012